TNF and idiopathic pulmonary fibrosis: While multiple studies have shown the therapeutic effects in animal models [140–142], a double-blind clinical trial of IPF patients treated with etanercept, a monoclonal antibody against TNF-α, improved neither the forced vital capacity nor the diffusing capacity of the lungs.